Erythropoiesis-Stimulating Agents: Dose and Mortality Risk
Hypo-responsiveness to erythropoiesis-stimulating agents (ESAs) has been associated with increased mortality in end-stage renal disease patients. It is not clear if this effect is related to the elevated ESAs dosage for targeting hemoglobin levels or underlying morbid conditions that lead to ESA resistance. We retrospectively evaluated from 2008 to death or December 2011, 28 consecutive incident hemodialysis patients. We identified 2 cohort of patients based on their mean annual ESAs dosage. The correlation between data was evaluated with the Spearman's rho test.
Source: Journal of Renal Nutrition - Category: Urology & Nephrology Authors: Guido Bellinghieri, Carmela Giuseppina Condemi, Salvatore Saitta, Gianluca Trifirò, Sebastiano Gangemi, Vincenzo Savica, Michele Buemi, Domenico Santoro Tags: Icurt Proceedings Source Type: research